BioVie ( (BIVI) ) just unveiled an announcement.
BioVie Inc., a clinical-stage biopharmaceutical company, has initiated a public offering of its class A common stock and warrants, aiming to raise approximately $3 million for working capital and general corporate purposes. The offering, managed by ThinkEquity LLC as the sole placement agent, involves nearly 2 million shares at $1.53 each, along with pre-funded and common warrants. The offering’s success hinges on market conditions and meeting customary closing criteria. This move offers investors the chance to engage with a company focused on developing treatments for liver disease and neurodegenerative disorders.
See more insights into BIVI stock on TipRanks’ Stock Analysis page.
